The shares of the Pharma company, specializing in manufacturing specialty medicines, vaccines, and general medicines, jumped upto 8 percent upon declaring Q4 results with a 36 percent rise in Profit Year on Year (YoY).
With a market capitalization of Rs. 49,585.15 crores on Wednesday, the shares of GlaxoSmithKline Pharmaceuticals Ltd jumped upto 8.4 percent, making a high of Rs. 3026.20 per share compared to its previous closing price of Rs. 2790.15 per share. GlaxoSmithKline Pharmaceuticals Ltd, engaged in manufacturing specialty medicines, vaccines, and general medicines, has announced its Q4 results as follows.
Its Revenue from operations rose by 5 percent YoY from Rs. 930 Crores in Q4FY24 to Rs. 974 Crores in Q4FY25, and it rose by 3 percent QoQ from Rs. 949 Crores in Q3FY25 to Rs. 974 Crores in Q4FY25.
Its Net Profit YoY rose by 36 percent from Rs. 194 Crores in Q4FY24 to Rs. 263 Crores in Q4FY25, and it rose by 14 percent QoQ from a profit of Rs. 230 Crores in Q3FY25 to Rs. 263 Crores in Q4FY25.
The earnings per share (EPS) for the quarter stood at Rs. 15.52, compared to Rs. 13.57 in the previous quarter. Along with this, the Board has recommended a final dividend of Rs.42/- per equity share on the face value of Rs.10 each for the year ended 31st March 2025.
GlaxoSmithKline Pharmaceuticals Ltd (GSK) is a debt-free company with strong promoter confidence, as promoters hold over 65 percent of its shares. Over the past three years, the company has achieved an impressive average net profit growth of 15.71 percent, reflecting its solid financial performance and stability.
Products portfolio & Services
GlaxoSmithKline Pharmaceuticals Ltd (GSK) is a leading Indian research-based pharmaceutical and healthcare company and a subsidiary of the global GSK group. Established on 13 November 1924 as H.J. Foster & Co. Limited, it has grown to become a major player in the Indian pharmaceutical sector, with its headquarters in India and a workforce of approximately 3,500 employees.
GSK Pharmaceuticals operates primarily in the areas of prescription medicines and vaccines. Its product portfolio spans a wide range of therapeutic areas, including anti-infectives, dermatology, gynecology, diabetes, oncology, cardiovascular disease, and respiratory diseases.
GSK is leading the Vaccines market with ~21.2 percent market share, which provides vaccines for the prevention of diseases such as hepatitis A and B, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, and cervical cancer, among others.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
